Noveris Health Sciences is trading 5.56% lower at CA$0.09, with biotech weakness and macro pressure weighing on growth-oriented shares.
- Opening-market weakness continued after a 10.00% decline on September 23.
- Biotech fell 2.04% as higher Treasury yields and crude prices pressured growth-oriented shares; the 10-year Treasury yield rose to 5.14%, a 19-year high.
- No company-specific announcement dated September 24 was found; the latest identified company news was the September 9 annual and special meeting update.